Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  De Felice, Francesca ^a   Marchetti, Claudia ^a   Palaia, Innocenza ^a   Musio, Daniela ^a   Muzii, Ludovico ^a   Tombolini, Vincenzo ^a   Panici, Pierluigi Benedetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 936559; DURVALUMAB; IMMUNOMODULATING AGENT; IPILIMUMAB; MPDL 33280A; MSB 0010718C; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ANOREXIA; CANCER CELL; CANCER IMMUNOTHERAPY; CLINICAL PRACTICE; COLITIS; DIARRHEA; DRUG TARGETING; EFFECTOR CELL; ENDOCRINE DISEASE; FATIGUE; FEMALE; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; KIDNEY FAILURE; LYMPHOCYTOPENIA; MELANOMA; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; NAUSEA; OVARY CANCER; PERICARDIAL EFFUSION; PNEUMONIA; RASH; REVIEW; SURVIVAL RATE; THYROID DISEASE; VOMITING; CLINICAL TRIAL (TOPIC); IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 84937681320     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/191832     Document Type: Review

References (49)

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015, " CA: Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
2. J. Prat, "New insights into ovarian cancer pathology, " Annals of Oncology, vol. 23, supplement 10, pp. x111-x117, 2012.
3. W. B. Coley, "Contribution to the knowledge of sarcoma, " Annals of Surgery, vol. 14, pp. 199-220, 1891.
4. E. F. McCarthy, "The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas, " The Iowa Orthopaedic Journal, vol. 26, pp. 154-158, 2006.
5. A. E. Chang and S. Shu, "Current status of adoptive immunotherapy of cancer, " Critical Reviews in Oncology/Hematology, vol. 22, no. 3, pp. 213-228, 1996.
6. R. N. Eskander and K. S. Tewari, "Immunotherapy: an evolving paradigmin the treatment of advanced cervical cancer, " Clinical Therapeutics, vol. 37, no. 1, pp. 20-38, 2015.
7. A. G. Baxter and P. D. Hodgkin, "Activation rules: the two-signal theories of immune activation, " Nature Reviews Immunology, vol. 2, no. 6, pp. 439-446, 2002.
8. A. Schietinger, M. Philip, and H. Schreiber, "Specificity in cancer immunotherapy, " Seminars in Immunology, vol. 20, no. 5, pp. 276-285, 2008.
9. R. D. Schreiber, L. J. Old, and M. J. Smyth, "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, " Science, vol. 331, no. 6024, pp. 1565-1570, 2011.
10. S. Matsueda and D. Y. Graham, "Immunotherapy in gastric cancer, " World Journal of Gastroenterology, vol. 20, no. 7, pp. 1657-1666, 2014.
11. M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J. Smyth, "Natural innate and adaptive immunity to cancer, " Annual Review of Immunology, vol. 29, pp. 235-271, 2011.
12. L. E. Kandalaft, D. J. Powell, N. Singh, and G. Coukos, "Immunotherapy for ovarian cancer: what's next?" Journal of Clinical Oncology, vol. 29, no. 7, pp. 925-933, 2011.
13. F. Ito and A. E. Chang, "Cancer immunotherapy, Current status and future directions, " Surgical Oncology Clinics of North America, vol. 22, no. 4, pp. 765-783, 2013.
14. C. Robert, L. Thomas, I. Bondarenko et al., "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, " The New England Journal ofMedicine, vol. 364, no. 26, pp. 2517-2526, 2011.
15. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, "The New England Journal of Medicine, vol. 366, no. 26, pp. 2455-2465, 2012.
16. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, " The New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
17. M. K. Callahan and J. D. Wolchok, "At the Bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy, " Journal of Leukocyte Biology, vol. 94, no. 1, pp. 41-53, 2013.
18. D.-H. Wang, L. Guo, and X.-H. Wu, "Checkpoint inhibitors in immunotherapy of ovarian cancer, " Tumor Biology, vol. 36, pp. 33-39, 2015.
19. D. F. Stroncek, C. Berger, M. A. Cheever et al., "New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer, " Journal of Translational Medicine, vol. 10, no. 1, article 48, 2012.
20. K. S. Peggs, S. A. Quezada, C. A. Chambers, A. J. Korman, and J. P. Allison, "Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies, " Journal of Experimental Medicine, vol. 206, no. 8, pp. 1717-1725, 2009.
21. P. S. Linsley, J. Bradshaw, J. Greene, R. Peach, K. L. Bennett, and R. S. Mittler, "Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement, " Immunity, vol. 4, no. 6, pp. 535-543, 1996.
22. T. Takahashi, T. Tagami, S. Yamazaki et al., "Immunologic self tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4, " Journal of Experimental Medicine, vol. 192, no. 2, pp. 303-310, 2000.
23. D. B. Page, M. A. Postow, M. K. Callahan, J. P. Allison, and J. D. Wolchok, "Immune modulation in cancer with antibodies, " Annual Review of Medicine, vol. 65, pp. 185-202, 2014.
24. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo, "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, " Immunity, vol. 11, no. 2, pp. 141-151, 1999.
25. H. Nishimura, T. Okazaki, Y. Tanaka et al., "Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice, " Science, vol. 291, no. 5502, pp. 319-322, 2001.
26. D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy, " Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
27. C. Kyi and M. A. Postow, "Checkpoint blocking antibodies in cancer immunotherapy, " FEBS Letters, vol. 588, no. 2, pp. 368-376, 2014.
28. A. Pedoeem, I. Azoulay-Alfaguter, M. Strazza, G. J. Silverman, and A. Mor, "Programmed death-1 pathway in cancer and autoimmunity, " Clinical Immunology, vol. 153, no. 1, pp. 145-152, 2014.
29. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastatic melanoma, " The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.
30. M.-L. Alegre and F. Fallarino, "Mechanisms of CTLA-4-Ig in tolerance induction, "Current PharmaceuticalDesign, vol. 12, no. 2, pp. 149-160, 2006.
31. F. S. Hodi, M. C. Mihm, R. J. Soiffer et al., "Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4712-4717, 2003.
32. F. S. Hodi, M. Butler, D. A. Oble et al., "Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 8, pp. 3005-3010, 2008.
33. ClinicalTrials, gov, "Phase II study of ipilimumab monotherapy in recurrent platinum sensitive ovarian cancer patients, " ClinicalTrials, gov Identifier NCT01611558, 2015, https://clinicaltrials. gov/ct2/show/NCT01611558.
34. A. Ribas, R. Kefford, M. A. Marshall et al., "Phase III randomized clinical trial comparing tremelimumab with standardof-care chemotherapy in patients with advanced melanoma, " Journal of Clinical Oncology, vol. 31, no. 5, pp. 616-622, 2013.
35. P. Bruhns, "Properties of mouse and human IgG receptors and their contribution to disease models, " Blood, vol. 119, no. 24, pp. 5640-5649, 2012.
36. Y. Bulliard, R. Jolicoeur, M. Windman et al., "Activating fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies, " Journal of Experimental Medicine, vol. 210, no. 9, pp. 1685-1693, 2013.
37. T. R. Simpson, F. Li, W. Montalvo-Ortiz et al., "Fc-dependent depletion of tumor-infiltrating regulatory t cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, " Journal of Experimental Medicine, vol. 210, no. 9, pp. 1695-1710, 2013.
38. M. K. Callahan, "A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors, " in Proceedings of the ASCO Annual Meeting, 2014, http://meetinglibrary, asco, org/content/130062-144.
39. S. L. Topalian, M. Sznol, D. F. McDermott et al., "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, " Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020-1030, 2014.
40. J. Hamanishi, M. Mandai, T. Ikeda et al., "Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer, " Journal of Clinical Oncology, vol. 32, abstract 5511, 2014, ASCO Annual Meeting.
41. E. B. Garon, A. Balmanoukian, O. Hamid et al., "Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC), " in Proceedings of the 15thWorld Lung Cancer Conference, MO18, 02, October 2013, http://abstracts, webges.com/wclc2013/myitinerary.
42. J.-C. Soria and R. A. Stahel, "PD-1 Inhibitors Raise Survival in NSCLC, " Cancer Discovery, vol. 4, no. 1, p. 6, 2014.
43. O. Hamid, C. Robert, A. Daud et al., "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, " The New England Journal of Medicine, vol. 369, pp. 134-144, 2013.
44. A. Varga, S. A. Piha-Paul, P. A. Ott et al., "Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results froma phase Ib study, " Journal of Clinical Oncology, vol. 33, abstract 5510, 2015.
45. G. J. Freeman, A. J. Long, Y. Iwai et al., "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, " Journal of Experimental Medicine, vol. 192, no. 7, pp. 1027-1034, 2000.
46. C. Heery, G. H. Coyne, R. A. Madan et al., "Phase I open-label, multiple ascending dose trial of MSB0010718C. An anti-PD-L1 monoclonal antibody, in advanced solid malignancies, " Journal of Clinical Oncology, vol. 32, abstract 3064, 2014, Proceedings of the 2014 ASCO Annual Meeting, http://meetinglibrary, asco. org/content/132657-144.
47. Merck SeronoDay-TheMerckGroup, http://www. merckgroup.com/en/investors/merck serono day. html.
48. M. L. Disis, M. R. Patel, S. Pant et al., "Avelumab (MSB0010718C). An anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib. open-label expansion trial, " Journal of Clinical Oncology, vol. 33, supplement 15, abstract 5509, 2015.
49. L. E. Kandalaft, G. T. Motz, J. Duraiswamy, and G. Coukos, "Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance, " Cancer and Metastasis Reviews, vol. 30, no. 1, pp. 141-151, 2011.